A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers

Advanced biliary tract cancers (ABTC) are among the deadliest malignancies with limited treatment options after progression on standard-of-care chemotherapy, which includes gemcitabine (GEM) and oxaliplatin (OX). The epidermal growth factor receptor inhibitor erlotinib has been explored in ABTC with...

Descripción completa

Detalles Bibliográficos
Autores principales: Goff, Laura W., Cardin, Dana B., Whisenant, Jennifer G., Du, Liping, Koyama, Tatsuki, Dahlman, Kimberly B., Salaria, Safia N., Young, Ruth T., Ciombor, Kristen K., Gilbert, Jill, Smith, Stephen James, Chan, Emily, Berlin, Jordan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306261/
https://www.ncbi.nlm.nih.gov/pubmed/27853997
http://dx.doi.org/10.1007/s10637-016-0406-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5306261/
https://www.ncbi.nlm.nih.gov/pubmed/27853997
http://dx.doi.org/10.1007/s10637-016-0406-z

Ejemplares similares